Cepheid (Nasdaq: CPHD) today announced the international availability of an update to Xpert® Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, ...
cre-carbapenem-resistant-enter The Food and Drug Administration (FDA) has cleared Xpert Carba-R Assay, the first test to detect specific genetic markers associated with bacteria that are resistant to ...
Xpert Carba-R Test is the First FDA-Cleared Molecular Test for Rapid Detection of Carbapenemase Producing Organisms Directly from Rectal Swab Specimens "The number of global incidents associated with ...
* Clears Xpert Carba-R Assay, test to detect specific genetic markers for certain antibiotic-resistant bacteria directly from clinical specimens Source text: (1.usa.gov/296qiLy) Further company ...
The Xpert Carba-R Assay tests specimens directly taken from patients, which are usually obtained by rectal swabs, for the presence of five different genetic markers that are associated with ...
The FDA has cleared expanded claims for the Xpert Carba-R, a molecular test for the detection of carbapenemase-producing gram-negative bacteria, from Sunnyvale, Calif.-based Cepheid Inc. The ...
Cepheid is developing a rapid test, known as Xpert Carba-R, for detecting multidrug-resistant pathogens. The test has several advantages over existing diagnostic methods. The company successfully ...
Cepheid has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for expanded claims for Xpert® Carba-R, the first FDA-cleared test for detection of carbapenem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results